Omeros (OMER) News
NASDAQ: OMERHealth CareBiotechnology: Pharmaceutical PreparationsUSD
13.21-0.80 (-5.71%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
OMER news summary
We found 11 recent headlines mentioning Omeros (OMER): 5 in the past week and 8 in the past 30 days, most often from Seeking Alpha, Investing.com, Business Wire. OMER is making an outsized move today, down 5.71% at $13.21, which often coincides with company-specific news. Check the latest headlines below for the likely catalyst. The most recent story, "Omeros Corporation Reports Third Quarter 2026 Financial Results", was published by Nasdaq on Nov 17, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Omeros headlines
- Omeros Corporation Reports Third Quarter 2026 Financial ResultsOmeros Corporation reported its financial results for the third quarter ended September 30, 2026. The company's lead product, YARTEMLEA (narsoplimab-wuug), generated gross revenue of $41.8 million in…Nasdaq
- Omeros expects Q4 2026 discontinued ops income of $5M-$6M while scaling YARTEMLEA education and outpatient useSeeking Alpha
- Why is Omeros stock sliding today?Investing.com
- Omeros Non-GAAP EPS of $0.06 beats by $0.08, revenue of $35.9M misses by $1.37MSeeking Alpha
- Omeros Corporation Reports Third Quarter 2026 Financial ResultsSEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the third quarter ended September 30, 2026, which…Business Wire
- Omeros Corporation to Announce Third Quarter Financial Results on November 16, 2026SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER) today announced that it will issue its financial results for the third quarter of 2026 on Monday, November 16, 2026 after market close.…Business Wire
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMERNEW YORK, Nov. 5, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Omeros Corporation ("Omeros" or the "Company") (NASDAQ: OMER). Such investors are advised to…PR Newswire
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMERNEW YORK, Oct. 29, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Omeros Corporation ("Omeros" or the "Company") (NASDAQ: OMER). Such investors are advised to…PR Newswire
- Why is Omeros stock sliding today?Investing.com
- Omeros shares slide following European regulatory setback for NarsoplimabInvesting.com
- Omeros transplant therapy snubbed in EU againSeeking Alpha